HTB

ICAAC 41st Chicago 2001

41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 16-19 December 2001

Low dose pegylated interferon is ineffective in treating HIV/HCV co-infected patients

Phenotypic resistance to ddI is less frequent than resistance to ZDV, 3TC and abacavir

Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients

Immune reconstitution more difficult with low baseline CD4+ T cell counts

HIV-1 may revert to less pathogenic strain a few days after starting HAART

Change from CCR5 to CXCR4 phenotype may affect immunologic responses

ddI EC (Videx) study confirms and clarifies dosing on an empty stomach

Swatch study: should we be cycling drugs?

New HIV drugs, resistance, pharmacogenomics

Antiretroviral therapy

Immunopathogenesis of HIV infection